Ibrutinib significantly outperformed ofatumumab as a second-line therapy for the treatment of relapsed chronic lymphocytic leukemia (CLL) in a head-to-head comparison of two Food and Drug Administration-approved drugs. This was a multicenter interim study published in the OnLine First edition of the New England Journal of Medicine. Ibrutinib (Imbruvica) is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival ...
Read MoreYou have just read an article categorized health
titled Support for Ibrutinib as Second-Line Therapy for CLL Enhanced in Phase 3 Study.
Written by:
editor - Sunday, June 1, 2014
There are currently no comments for "Support for Ibrutinib as Second-Line Therapy for CLL Enhanced in Phase 3 Study"
Post a Comment